[1]
|
Anderson, L. (2005) Candidate-based proteomics in the search for biomarkers of cardiovascular disease, The Journal of Physiology, 563(1), 23-60.
|
[2]
|
Gotto, A.M, Jr, and Farmer, J.A. (2006) Drug insight: The role of statins in combination with ezetimide to lower LDL cholesterol. Nature Clinical Practice Cardiovascular Medicine, 3(12), 664-672.
|
[3]
|
Ugawa, T., Kakuta, H., Moritani, H., Inagaki, O. and Shikama, H. (2003) YM-53601, a novel squalene synthase inhibitor, suppresses lipogenic biosynthesis and lipid secretion in rodents. British Journal of Pharmacology, 139(1), 140-146.
|
[4]
|
Tuzikov, F.V., Tuzikova, N.A., Galimov, R.V., Panin, L.E. and Nevinsky, G.A. (2002) General model to describe the structure and dynamic balance between different human serum lipoproteins and its practicl application. Medical Science Monitor, 8(6), pp. 79-88.
|
[5]
|
Dumortier, G., Grossiord, J.L., Agnely, F. and Chaumeil, J.C. (2006) A review of poloxamer 407 pharmaceutical and pharmacological Characteristics. Pharmaceuticals Research, 23(12), 2709-2728.
|
[6]
|
Leon, C., Wasan, K.M., Sachs-Barrable, K. and Johnston, T.P. (2006) Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression. Pharmaceuticals Research, 23(7), 1597-1607.
|
[7]
|
Kim, H.Y., Jeong, D.M., Jung, H.J., Jung, H.J., Yozokawa, T. and Choi, J.S. (2008) Hypolipidemic effects of Sophora Flavescens and its constituents in poloxamer 407-induced hyperlipidemic and cholesterol-fed rats. Biological & Pharmaceutical Bulletin, 31(1), 73-78.
|
[8]
|
Johnston, T.P. and Palmer, W.K. (1997) The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats. Pharmacotherapy, 17(2), 342-347.
|
[9]
|
Johnston, T.P., Baker, J.C., Hall, D., Jamal, S., Palmer, W.K. and Emeson, E.E. (2000) Regression of poloxamer 407-induced atherosclerotic lesions in C57BL/6 mice using atorvastatin. Atherosclerosis, 149(2), 303-313.
|
[10]
|
Johnston, T.P., Nguyen, L.B., Chu, W.A. and Shefer, S. (2001) Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. International Journal of Pharmaceutics, 229(1-2), 75-86.
|
[11]
|
Nash, V.J., Johnston, T.P. and Palmer, W.K. (1996) Effects of nicotinic acid on poloxamer 407-induced hyperlipidemia. Pharmacotherapy, 16(1), 10-15.
|
[12]
|
Johnston, T.P., Li, Y., Jamal, A.S., Stechschulte, D.J. and Dileepan, K.N. (2003) Poloxamer 407-induced atherosclerosis in mice appears to be due to lipid derangements and not due to its direct effects on endothelial cells and macrophages. Mediators of Inflammation, 12(3), 147- 155.
|
[13]
|
Johnston, T.P. (2009) Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1, and E-selectin, in C57BL/6 Mice. Journal of Pharmacy and Pharmacology, 61(12), 1681-1688.
|
[14]
|
Johnston, T.P. and Waxman, D.J. (2008) The induction of atherogenic dyslipidemia in poloxamer 407-treated mice is not mediated through PPARα. Journal of Pharmaceutical Sciences, 60(6), 753-759.
|
[15]
|
Otvos, J.D. (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clinical Laboratory, 48(3-4), 171-180.
|
[16]
|
Pelton, P.D, Patel, M. and Demarest, K.T. (2005) Nuclear receptors as potential targets for modulating reverse cholesterol transport, Current Topics in Medicinal Chemistry, 5(3), 265-282.
|
[17]
|
Jeyarajah, E.J., Cromwell, W.C. and Otvos, J.D. (2006) Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clinics in Laboratory Medicine, 26(4), 847-870.
|
[18]
|
Cromwell, W.C. and Otvos, J.D. (2006) Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. American Journal of Cardiology, 98(12), 1599-1602.
|
[19]
|
Bozóky, Z., Fül?p, L. and K?hidai, L. (2001) A short run new analytical ultracentrifugal micromethod for determining low-density lipoprotein sub-fractions using Sch- lieren refractometry. European Biophysics Journal, 29(8), 621-627.
|
[20]
|
Barcia, A.M. and Harris, H.W. (2005) Triglyceride-rich lipoproteins as agents of innate immunity, Clinical Infectious Diseases, 41(10), S498-503.
|
[21]
|
Tanaka, H., Ishida, T., Johnston, T.P., Yasuda, T., Ueyama, T., Kojima, Y., Kundu, R.K., Quertermous, T. and Hirata, K.-I. (2009) Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia. Journal of Atherosclerosis and Thrombosis, 16(4), 327-338.
|
[22]
|
Gatica, L.V., Vega, V.A., Zirulnik, F., Oliveros, L.B. and Gimenez, M.S. (2006) Alterations in the lipid metabolism of rat aorta: Effects of vitamin A deficiency. Journal of Vascular Research, 43(6), 602-610.
|
[23]
|
Brown, R.J. and Rader, D.J. (2007) Lipases as modulators of atherosclerosis in murine models. Current Drug Targets, 8(12), 1307-1319.
|
[24]
|
Ballabio, A. and Gieselmann, V. (2009) Lysosomal disorders: from storage to cellular damage. Biochimica et Biophysica Acta, 1793(4), 684-696.
|
[25]
|
Johnston, T.P. and Palmer, W.K. (1993) Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. Biochemical Pharmacology, 46(6), 1037-1042.
|
[26]
|
Millar, J.S., Cromley, D.A, McCoy, M.G., Rader, D.J. and Billheimer, J.T. (2005) Determining hepatic triglyceride production in mice: Comparison of poloxamer 407 with triton WR 1339. Journal of Lipid Research, 46(9), 2023-2028.
|
[27]
|
Schneider, P., Korolenko, T.A. and Busch, U. (1997) A review of drug-induced lysosomal disorders of the liver in man and laboratory animals, Microscopy Research and Technique, 36(4), 253-275.
|
[28]
|
Johnston, T.P. (2004) The P-407-induced murine model of dose-controlled hyperlipidemia and atherosclerosis: A review of findings to date. Journal of Cardiovascular Pharmacology, 43(4), 595-606.
|
[29]
|
Kuzman, D., Fon Tacer, K., Cerne, M., Rezen, T., Acimovic, J., Cegovnik, U., Kocjan, D., Urleb, U. and Rozman, D. (2009) Modulation of hepatic transcriptome in the poloxamer P-407 hyperlipidemia mouse model. Acta Chimica Slovenica, 56(1), 262-269.
|
[30]
|
Fruchart, J.C. and Duriez, P. (2006) Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc), 42(1), 39-64.
|
[31]
|
Butler, J.A., Hagen, T.M. and Moreau, R. (2009) Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Archives of Biochemistry and Biophysics, 485(1), 63-71.
|
[32]
|
Mora, S., Otvos, J.D., Rifai, N., Rosenson, R.S., Buring, J.E. and Ridker, P.M. (2009) Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119(17), 931- 939.
|
[33]
|
Zhou, X., Johnston, T.P., Johansson, D., Parini, P., Funa, K., Svensson, J. and Hansson, G.K. (2009) Hypercholesterolemia leads to elevated TGF-beta 1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice, Atherosclerosis, 204(2), 381-387.
|
[34]
|
Gotto, A.M. and Farmer, J.A. (2007) Atherosclerosis: Pathogenesis, morphology, and risk factors. Willerson J.T., Wellens H., Cohn J.N. and Holmes D.R., Jr. Edition, Cardiovascular Medicine, 3rd Edition, Springer, London, pp. 1593-1613.
|